ABSTRACT
INTRODUCTION
Preterm birth is associated strongly with neonatal brain injury and causes 50% of all neurological disabilities in childhood [1] [2] [3] . Neonates born before 32 weeks of gestation have the highest risk of poor neurological outcome [4] [5] [6] [7] . Severe brain injury on ultrasound increases the risk of developing cerebral palsy and motor disability 8 . Milder types of brain injury, such as intraventricular hemorrhage (IVH) Grades I and II, also show an independent association with neurosensory impairment, developmental delay and cerebral palsy 9 . Therefore, identification of the type and severity of brain injury is predictive of the prognosis of preterm born infants.
Serial ultrasound examination is used widely to diagnose brain injury and has a variable sensitivity and specificity. The accuracy depends on the severity and type of cerebral injury, the experience of the operator and the use of a standardized ultrasound protocol 10 . Since brain injury is strongly associated with poor neonatal prognosis, the evaluation of pharmacological interventions for threatened preterm birth should include their effect on neonatal brain injury. A recently published Cochrane review showed the neuroprotective effects of magnesium sulfate administered during preterm delivery 11 . As a result of this neuroprotective ability, a reduction in cerebral palsy at 2 years of age and mortality has been described 12 . Interventions aimed at improving neonatal outcome in preterm birth also include administration of tocolytic drugs to women with threatened preterm birth, of which the most commonly used are atosiban, an oxytocin receptor antagonist, and nifedipine, a calcium channel blocking agent 13 . Nifedipine, through its calcium-blocking properties, might have a similar protective effect on brain injury to magnesium sulfate. Several in-vitro and in-vivo studies on nifedipine indicate a neuroprotective effect based on reduction of ischemic neuronal cell damage and reduction of intracerebral blood pressure fluctuations [14] [15] [16] . Atosiban is not assumed to have direct neuroprotective effects. In addition, both drugs may have an indirect effect on brain injury by delaying preterm birth.
In view of the high incidence of brain injury in premature neonates and the widespread use of nifedipine and atosiban in the management of threatened preterm birth, an evaluation of the neuroprotective effects of these drugs is needed. We hypothesized that tocolysis with nifedipine, compared with atosiban, in women with threatened preterm birth reduces overall brain injury in neonates born prematurely.
METHODS

Study design
This was a secondary analysis of the APOSTEL-III (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labor) trial (Dutch Clinical Trial Registry, no. NTR2947) 17 . The study protocol has been reported previously 13 . This was a randomized clinical trial conducted in 19 hospitals in The Netherlands and Belgium that compared two commonly used tocolytic drugs, atosiban and nifedipine, in women with threatened preterm birth between 25 and 34 weeks of gestation. Threatened preterm birth was defined as at least three contractions per 30 min and one of (1) a cervical length of < 10 mm, (2) a cervical length of 11-30 mm and a positive fibronectin test, or (3) ruptured membranes 13 . Women were randomized to administration of nifedipine or atosiban for 48 h. Corticosteroids and antibiotics were administered according to local protocol. The primary outcome for the APOSTEL-III study was a composite adverse perinatal outcome, including perinatal mortality, bronchopulmonary dysplasia, sepsis, IVH, periventricular leukomalacia and necrotizing enterocolitis. The APOSTEL-III trial was approved by the ethics committee of the Academic Medical Center Amsterdam (reference no. MEC AMC 09/258) and the boards of management of all participating hospitals. All women provided written informed consent.
Study population
For this secondary analysis, we selected a cohort of all women who delivered ≤ 32 weeks of gestation in the University Medical Center Utrecht (UMCU) and Academic Medical Center Amsterdam (AMC). This subgroup was selected because neonates born before 32 weeks of gestation have the highest risk of poor neurological outcome. Neonates born with lethal congenital anomalies (not known at the time of inclusion) and those with outcome missing were excluded, as were their mothers.
Maternal characteristics included maternal age at randomization, body mass index, gestational age at randomization, parity, multiple pregnancy, preterm prelabor rupture of membranes and tocolysis before randomization. Perinatal characteristics consisted of total tocolysis time and interval from start of tocolysis until delivery and were evaluated to show comparable exposure to study medication in both groups. Administration of a full course of antenatal corticosteroids was defined as two doses with the first dose at least 48 h before birth. As the initial first dose of steroids is given at the same time as the start of tocolysis, a full course of steroids also indicates the percentage of pregnancies with a prolongation of pregnancy more than 48 h. Suspicion of intrauterine infection was defined as maternal temperature > 37.8
• C, fetal tachycardia (heart rate > 150 bpm) or maternal tachycardia (heart rate > 120 bpm). Cesarean section included elective and emergency Cesarean sections with different indications. Cesarean section for fetal distress is shown separately. Postnatal characteristics consisted of gestational age at birth, birth weight and birth-weight Z-score. A low Apgar score was defined as an Apgar < 7 after 5 min and asphyxia if umbilical arterial pH was < 7.05 combined with a base deficit > 12 mmol/L. Arterial umbilical cord pH was also individually determined as a continuous variable. Primary intubation includes all infants with an immediate intubation in the delivery room. Intensive perinatal resuscitation was defined as need for insufflation breaths or a more intensive treatment for resuscitation. Severe neonatal morbidity requiring treatment during neonatal intensive care unit (NICU) admission was also determined, including hypotension (requiring inotropics), infant respiratory distress syndrome (requiring treatment with one or more courses of surfactant), need for mechanical ventilation, culture-proven sepsis, persistent ductus arteriosus (requiring treatment with one or more courses of indomethacin or ibuprofen and/or surgical treatment), necrotizing enterocolitis (including conservative and surgical treatment) and mortality.
Outcome measures
All neonates underwent serial ultrasound scanning during admission to NICU or neonatal medium care unit (NMCU), from day 0 until discharge home or transfer to another hospital. To minimize observer variability, the ultrasound scans were all reviewed by one experienced neonatologist (D.C.V.), who was blinded to study medication and perinatal events.
Primary outcome was defined as the presence of brain injury. Secondary outcome included the severity of brain injury, i.e. mild or severe, as well as the components of the primary outcome. The grade of brain injury, as well as classification into mild and severe injury, was evaluated according to abnormalities seen on ultrasound during NICU or NMCU admission, as presented in Table 1 . Neonates that did not undergo ultrasound examination after day 6 were graded as missing score for PVL Grade 1.
Statistical analysis
Since only a subset of the APOSTEL-III population was included in this secondary analysis, patients in Twins are strongly correlated due to similar intrauterine and perinatal exposure to factors influencing brain injury, and therefore mixed-effect models and general estimating equations are often recommended to account for this correlation. However, in this particular situation, due to a low percentage of twins and a binary outcome, ordinary logistic regression is recommended 18 . Therefore, logistic regression analysis in a combined group with multiples and singletons was used to determine association with outcome. To adjust for potential confounders introduced by the selection of a subgroup of patients in this study, we also performed analyses to adjust for differences in baseline characteristics and known risk factors (gestational age at inclusion). Furthermore, a subgroup analysis of women delivering within 24 h after termination of tocolysis was performed to analyze the immediate effect of study medication on the neonatal brain during delivery.
RESULTS
Study population and patient characteristics
In the APOSTEL-III study, 248 women were randomized to nifedipine and 255 to atosiban, giving birth to 297 and 294 children, respectively. In the two centers (UMCU and AMC) participating in this secondary analysis, 82 women randomized to nifedipine and 90 women randomized to atosiban presented with threatened preterm birth at ≤ 32 weeks of gestation. Of these, 56% (46/82) of women who received nifedipine, compared with 62% (56/90) of those who were treated with atosiban delivered ≤ 32 weeks of gestation (P = 0.41). Therefore, 102 women were included in the analysis, resulting in 119 children born alive between 25 and 32 weeks of gestational age. Two neonates were excluded because of lethal congenital anomalies, resulting in 117 neonates eligible for data analysis, 51 in the nifedipine and 66 in the atosiban group (Figure 1) .
Maternal baseline characteristics are presented in Table 2 . Maternal characteristics were comparable in both groups, except for median maternal age, which was higher in women in the nifedipine group compared with those in the atosiban group. Multiple pregnancy was present in six (13%) of the women allocated to nifedipine and nine (16%) in the atosiban group. Perinatal characteristics of the children are shown in Table 3 . Total tocolysis time, administration of a full course of steroids and administration of magnesium sulfate were comparable between the groups. The rate of Cesarean section was similar in both groups (33% in the nifedipine group vs 20% in the atosiban group, P = 0.09). In women delivered by Cesarean section, there was a significant difference (P = 0.02) in the number of Cesarean deliveries due to fetal distress between the nifedipine (47%) group and the atosiban (15%) groups. All postnatal characteristics were comparable between the groups, except for the umbilical arterial cord pH at birth, which was significantly higher in the nifedipine compared with the atosiban group (7.32 vs 7.26, P = 0.01) ( Table 3) . Due to failure to obtain blood gas measurements, there was a high percentage of missing values in both groups.
Outcomes
In total, 540 ultrasound examinations were reviewed during NICU and NMCU admission, including 203 in the nifedipine and 337 in the atosiban group. The median (interquartile range) number of scans analyzed per patient was 3 (3) (4) (5) in the nifedipine group and 5 (3-7) in the atosiban group. The primary outcome (total brain injury) based on the ultrasound findings, and classification of severity of brain injury, is presented in Table 4 . In total, brain injury was observed in 22 (43.1%) neonates in the nifedipine group and 37 (56.1%) neonates in the atosiban group (OR, 0.60; 95% CI, 0.29-1.24). Components of the primary outcome were not significantly different between the study groups (Table 4) . Mild brain injury was seen in 17 (33.3%) cases in the nifedipine group compared with 32 (48.5%) in the atosiban group (OR, 0.53; 95% CI, 0.25-1.13) and severe brain injury in five (9.8%) in the nifedipine compared with five (7.6%) in the atosiban group (OR, 1.33; 95% CI, 0.36-4.85).
Adjustment for maternal age and gestational age at randomization showed similar rates of brain injury (OR, 0.58; 95% CI, 0.27-1.27). Furthermore, no difference in brain injury was detected in a selected group of patients born within 24 h after administration of tocolysis (OR, 0.7; 95% CI, 0.27-1.85).
Cesarean section with suspected fetal distress as indication was the only clinically relevant perinatal factor that was more often seen in the nifedipine group. Therefore, logistic regression was performed to assess whether there was an association between Cesarean section and brain injury, which showed that brain injury was significantly reduced by Cesarean section (OR, 0.32; 95% CI, 0.13-0.77). Multivariate analysis with Cesarean section for fetal distress and type of tocolysis decreased the effect of nifedipine on reduction of brain injury (OR, 0.68; 95% CI, 0.31-1.44).
DISCUSSION
This study found no significant difference in the effect of nifedipine compared with atosiban on brain injury in neonates born before 32 weeks of gestation. There was no difference in type and severity of brain injury during NICU and NMCU admission. These results are in line with the previously reported similar incidence in severe types of brain injury in small randomized controlled trials comparing nifedipine and atosiban [19] [20] [21] .
A strength of this study is that data have been collected in a randomized setting with administration of nifedipine or atosiban being the only difference between Data are median (interquartile range) or n (%). *Data missing for 24 neonates in nifedipine and 14 in atosiban group. †Data missing for 24 neonates in nifedipine and 13 in atosiban group. CPAP, continuous positive airway pressure; IRDS, infant respiratory distress syndrome; NEC, necrotizing enterocolitis; PDA, persistent ductus arteriosus; PEEP, positive end expiration pressure. Table 4 Brain injury evaluated during admission to neonatal intensive care unit (NICU) or medium care unit (NMCU) according to findings on ultrasound examination, in 117 children born ≤ 32 weeks to mothers treated with nifedipine or atosiban for threatened preterm birth Some patients had more than one type of brain injury. *Only patients with ultrasound examination after day 7 included (atosiban, n = 47; nifedipine, n = 29). IVH, intraventricular hemorrhage; OR, odds ratio; PVL, periventricular leukomalacia.
There are also limitations to our study. In this secondary analysis, we used a non-randomly selected subgroup of the randomized population. Baseline characteristics, however, appeared to be similar between the groups, with the exception of maternal age. As this variable was not seen as a clinically relevant factor influencing neonatal outcome, the study groups in the secondary analysis were assumed to be comparable. Nevertheless, brain injury is a multifactorial problem with peri-and postnatal factors influencing outcome. As most of the peri-and postnatal factors are equally distributed between the study medication groups, we assumed type of tocolysis as the most influential factor on brain injury. These assumptions should be made with caution as the inclusion criteria for this secondary analysis reduced the sample size leading to an increased risk of underpowering and enabling clinically relevant risk factors to influence outcome without showing significance. Another limitation of this study was selection bias arising from analysis of a subset of a study, i.e. only neonates born ≤ 32 weeks of gestation. To minimize the selection bias, we tested if there was a difference in effectiveness. A significant difference in women included and delivered ≤ 32 weeks of gestation was observed. Furthermore, this study was underpowered for the outcome studied, having only a power of 42% to detect the observed relative risk of 0.80. If this relative risk holds true, a sufficiently powered study (e.g. power of 80%) would have required 500 infants. However this was the first study investigating this outcome. Our study would have been able to exclude the possibility of extreme effects.
The only perinatal outcome in our study that was significantly different between the two groups was incidence of Cesarean delivery due to fetal distress, with the number of Cesarean sections for fetal distress being higher in the nifedipine group. Several Doppler studies show significant changes in fetal and placental circulation after nifedipine exposure, suggesting that nifedipine may cause fetal distress 22, 23 . In contrast, these studies reported no influence of nifedipine on fetal heart rate, nor did de Heus et al. in a direct comparison between nifedipine and atosiban exposure 24 . These results are supported by Salim et al. 20 and Valdés et al. 25 reporting lower incidence of Cesarean delivery in the group treated with nifedipine as compared with atosiban and betamimetics, respectively. Additional analysis within our study showed that Cesarean section is associated with a significant reduction in brain injury. These findings are in line with previously published data in extremely low birth-weight neonates 26, 27 . However, two recently published reviews of literature found inconclusive evidence on the benefits of Cesarean section on brain injury and neurodevelopmental outcome 28, 29 . Statistical analysis of the fetal presentation between the medication groups was not possible due to small groups. Review of the cases in our study showed no influence of breech presentation on fetal distress as outcome (50% (n = 4) breech in the nifedipine group, 100% (n = 2) breech in the atosiban group). Adding Cesarean section (for fetal distress) in the multivariate analysis increased the OR value closer to 1. Therefore, the effect of nifedipine on brain injury is smaller when corrected for Cesarean section on fetal indication. Since evidence is inconclusive and the population in our study is small, it is not possible to conclude as to whether lower incidence of brain injury in the nifedipine group can be explained by higher rates of Cesarean sections, protecting the infants against prolonged perinatal asphyxia.
Magnetic resonance imaging (MRI) has shown higher sensitivity and specificity in determining type and severity of brain injury compared with ultrasound. However, MRI is indicated only in the first days of postnatal life if there are signs of neurological disability (e.g. hypotonia and convulsions) and at term in order to predict neurodevelopmental outcome 30, 31 . As a result, only a minority of the included patients had MRI, thus precluding a more specific analysis of ischemic brain injury in our population.
The added value of this study is that all types of brain injury, including mild injury, were assessed, and it was shown that mild types of brain injury were comparable between the two groups. This is important since there is increasing evidence supporting that mild brain injury, such as Grades I-II IVH, is also associated with poor neurodevelopmental outcome 32, 33 . Therefore, a significant difference in outcome of mild brain injury could also be clinically relevant. In our study, mild IVH (Grades I-II) accounted for 64.4% of any type of brain injury. As nifedipine could lead to a reduction of fluctuations in blood pressure, especially during delivery, we assumed a protective effect of nifedipine on development of IVH. A recent Cochrane meta-analysis showed a non-significantly lower incidence of IVH when using nifedipine compared with any other type of tocolysis 34 . Our results showed no difference between atosiban and nifedipine for incidence of total IVH as well as for each grade of IVH separately.
The subgroup analysis of patients that delivered during or within 24 h after administration of tocolytic drugs provided data on the possible direct effect of the drugs during delivery. Nifedipine is most likely to have an effect on the fetus while it is present in the blood during delivery, as it crosses the placenta with a ratio of 0.77-0.99 compared with atosiban, which has a minimal placental transfer of 0.124 [35] [36] [37] . However, it is uncertain whether clinically relevant serum levels are reached in the fetus during tocolysis. Our study implies that there is no direct effect of nifedipine, as neonates born within 24 h after tocolysis showed no difference in incidence of brain injury.
In conclusion, nifedipine administered as tocolytic treatment to women with threatened preterm birth is not associated with a reduction in brain injury in prematurely born neonates, when compared with administration of atosiban.
